Induced pluripotent stem cells (iPSCs) are helping researchers study amyotrophic lateral sclerosis (ALS) in more human-relevant, patient-specific ways. By differentiating patient-derived iPSCs into motor neurons and other relevant cell types, scientists can investigate disease-associated phenotypes, examine mutation-specific effects, and build experimental models for early therapeutic research. In this article, we look at how iPSC models have advanced ALS research through studies involving TDP-43- and SOD1-associated disease biology.
What are iPSCs used for in ALS research?
iPSCs are used to generate patient-specific motor neuron models that help researchers study ALS-associated pathology, investigate disease phenotypes, and test mechanistic hypotheses in human cells.²˒³
Why are iPSCs valuable for ALS research?
They allow scientists to examine disease-relevant phenotypes in the cell types mostly affected in ALS, while preserving the patient’s genetic background.¹˒²˒³
What have iPSC models revealed about ALS?
Studies using iPSC-derived motor neurons have helped researchers investigate disease-associated phenotypes linked to TDP-43 and SOD1, including mutation-specific effects and broader cellular dysfunction relevant to overall neurodegeneration.²˒³
Why do these models matter for translational research?
iPSC-based ALS models provide a human-relevant framework for mechanistic research and early therapeutic evaluation, though findings still need to be supported by broader preclinical and clinical validation.¹˒³
ALS is a progressive neurodegenerative disease that affects upper and lower motor neurons, leading to worsening muscle weakness, loss of function, and ultimately respiratory failure. Although the clinical picture of ALS has been studied for decades, understanding its biology at the cellular level remains challenging. One reason is simple: the cell type most affected in ALS, the motor neuron, is not easily available for direct study in living patients.¹
Induced pluripotent stem cells, or iPSCs, have become an important tool for addressing that challenge. By reprogramming adult patient cells into a pluripotent state and differentiating them into motor neurons, researchers can study ALS-associated cellular changes in a more disease-relevant human system.²˒³
In this article, we explore how iPSCs are being used in ALS research, what these models have revealed about disease biology, and why they continue to matter in translational neuroscience.
ALS is not a single-pathway disease. It involves a complex mix of genetic, cellular and enviromental factors. Some of the cellular processes affected by ALS include RNA processing, protein mislocalization, oxidative stress, mitochondrial dysfunction, disrupted axonal transport, and endoplasmic reticulum stress.¹˒³ This complexity exacerbates the need for a disease model that can faithfully recapitulate human biology.
iPSC technology gives researchers a way to model ALS using patient-derived cells that retain disease-associated genetic context. Once differentiated into motor neurons, these cells can be used to investigate how specific mutations contribute to ALS progression.²˒³
This has been especially useful in studies of genetically defined (familial) ALS. Rather than relying on in silico or animal models, researchers can examine cellular phenotypes in iPSC-derived motor neurons derived from patients with identified ALS risk variants. That makes it easier to ask targeted questions about mechanism, compare mutant and control lines, and build more informative experimental workflows.²˒³
Just as importantly, iPSC-derived ALS models help bridge discovery and translational research. They provide a controlled framework for examining disease-associated biology in vitro and, in some cases, for evaluating whether potential interventions influence those phenotypes.²˒³
One of the major strengths of human iPSC-derived ALS models is that they more faithfully recapitulate selected features of disease biology compared to animal models. In iPSC-derived motor neurons, these features may include altered protein localization, cellular stress responses, transcriptional changes, or increased neuronal vulnerability.²˒³
This does not mean that every iPSC-derived model captures the full complexity of ALS. But these systems can reveal biologically meaningful aspects of disease that are impossible to study in living patients. In that sense, their value lies not in reproducing every dimension of ALS, but in allowing researchers to isolate and study specific mechanisms in a human cellular context.¹˒²˒³
In ALS research, two especially important discoveries involve TDP-43- and SOD1-associated pathologies. Together, these examples show how iPSC-derived motor neurons can support both mechanistic insights and early-stage therapeutic investigation.²˒³
Abnormal TDP-43 function is one of the most widely recognized pathological features in ALS. In many forms of the disease, TDP-43 shifts from its normal nuclear role and becomes abnormally localized in the cytoplasm, where it is associated with pathological inclusions and broader cellular dysfunction.¹˒²
To study this process in a more disease-relevant system, researchers have generated iPSCs from ALS patients and differentiated them into motor neurons. In the Bilican et al. study, patient-derived lines recapitulated aspects of TDP-43 proteinopathy and revealed cell-type-specific vulnerability, helping demonstrate that human iPSC-derived motor neurons could capture meaningful disease-associated phenotypes in vitro.²
The significance of this kind of model is not only that it reflects a known feature of ALS pathology. It is that it gives researchers a way to examine how TDP-43-associated dysfunction may influence motor neuron health in a human system that is experimentally accessible. That can support studies of neuronal vulnerability, disease-associated stress responses, and mutation-linked cellular effects.²
These models are also useful because they create a platform for downstream research. Once a disease-relevant phenotype is established in human motor neurons, researchers can use that system to ask more refined mechanistic questions and, where appropriate, explore whether experimental interventions affect the phenotype.²
Mutations in the SOD1 gene are associated with certain familial forms of ALS and have been studied extensively in both animal and human-based systems. Using iPSC-derived approaches, SOD1-mutant motor neuron models have helped researchers investigate how a defined genetic mutation can disrupt cellular pathways linked to neurodegeneration.³
The Kiskinis et al. study is especially important because it paired patient-derived SOD1-mutant motor neurons with genetically corrected isogenic controls. That design helped researchers identify transcriptional and functional changes tied more directly to the SOD1 mutation itself, including signatures linked to oxidative stress, mitochondrial dysfunction, altered subcellular transport, and ER stress..³
This type of study illustrates one of the most powerful uses of iPSC technology in disease research: the ability to compare highly similar cell lines that differ only in a singular genetic locus. That helps reduce background noise and strengthens interpretation when researchers are trying to connect genotype to phenotype.³
For ALS research, that matters because it moves the field beyond broad disease description and toward more precise questions about mechanism. SOD1-mutant iPSC-derived motor neuron models have therefore become an important tool for understanding how specific mutations influence cellular behavior and for building more targeted experimental systems for therapeutic research.³
Taken together, TDP-43- and SOD1-based studies show why iPSCs have become so valuable in ALS research. They allow investigators to study disease-associated phenotypes in human motor neurons, preserve meaningful aspects of patient genetic background, and building models tailored to answer specific biological questions.²˒³
These systems are especially useful in a disease like ALS, where direct access to affected neural tissue is limited and the underlying biology is highly heterogeneous. iPSC-derived models do not eliminate that complexity, but they do provide a more flexible and human-relevant platform for studying it.¹˒²˒³
They also fit well within a broader translational workflow. iPSC-based ALS models can support target discovery, mechanistic investigation, and early therapeutic testing, helping researchers generate data that may guide more advanced preclinical work. At the same time, findings from these models still need to be interpreted carefully and validated through additional systems and, ultimately, clinical research.¹˒³
As iPSC workflows continue to improve, their role in ALS research will likely keep expanding. Advances in differentiation, genome editing, assay design, and phenotypic analysis are making it easier to build more refined motor neuron models and ask more precise questions about disease biology.²˒³
For ALS researchers, that progress is important because the disease is biologically complex and clinically heterogeneous. Tools that help clarify mechanism in a patient-specific, human-relevant framework can contribute meaningfully to both discovery and translational science.¹˒³
While iPSCs are not a complete answer to every challenge in ALS research, they have clearly strengthened the field’s ability to study disease-associated cellular dysfunction in vitro. That makes them an increasingly important part of the research toolkit for understanding ALS and evaluating new therapeutic ideas.²˒³
iPSCs have become an important tool in ALS research by enabling patient-specific motor neuron models that support the study of disease-associated phenotypes in human cells. Through work involving TDP-43- and SOD1-associated pathology, these models have helped researchers investigate cellular mechanisms, examine mutation-specific effects, and strengthen early translational research.²˒³
Their value lies in their ability to bring greater biological relevance to preclinical studies. By giving scientists access to human motor neurons derived from patients, iPSC-based models help connect clinical genetics to cellular phenotype in ways that can inform both mechanistic understanding and therapeutic exploration.²˒³
As ALS research continues to evolve, iPSCs are likely to remain an important platform for studying how neurodegeneration unfolds and how more targeted research strategies can be built around human-relevant disease models.¹˒²˒³
Contributing Author:
Jorge Urresti, PhD
Scientific Lead
iXCells Biotechnologies
With over a decade of experience in cellular biology and preclinical research, iXCells delivers human-relevant models that help researchers improve predictability and move new therapies forward.
